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Background. Loss of antibody reactivity against linear epitopes of parvovirus B19 (B19) capsid proteins VP1
and VP2 occurs after infection; however, it is unclear whether B cell memory is established against linear epitopes.
Methods. B cell enzyme-linked immunospot assay was used to evaluate B19-specific B cell memory in volunteer
donors ( ).np 22
Results. B cell memory is maintained against conformational epitopes of VP2 and is absent against linear
epitopes of VP2. Individuals seronegative for IgG against the unique region of VP1 have detectable B cell memory,
with the potential to mount a humoral response on reexposure to B19. Conversely, in mice immunized with VP2,
long-lasting IgG against linear epitopes of VP2 and a strong B cell–memory response are observed.
Conclusions. B cell memory is established and maintained against conformational epitopes of VP2 and against
linear epitopes of VP1 but not against linear epitopes of VP2. These findings further our understanding of the
immune response to B19 and suggest that analysis of B19-specific B cell memory merits consideration for future
B19-vaccine studies.
Parvovirus B19 (B19) is a small, nonenveloped eryth-
rovirus that usually causes a mild, self-limiting disease
(called “erythema infectiosum”) in children. However,
immunocompromised patients (such as patients with
HIV or patients with cancer who are undergoing che-
motherapy), pregnant women, and, increasingly, trans-
plant recipients are at significant risk for B19 infection
[1, 2]. Many such individuals are unable to produce
neutralizing antibodies to clear the virus, and this can
lead to a persistent infection resulting in anemia [1].
It is significant that many blood-product companies
have begun to implement screening protocols to min-
imize the B19 viral load in such blood-derived prod-
ucts as packed red blood cells, albumin, and intrave-
nous immunoglobulin [3].
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B19 encodes 3 main proteins: a nonstructural pro-
tein, NS1 (77 kDa), and 2 structural proteins, VP1 (83
kDa) and VP2 (58 kDa) [4]. The latter 2 proteins, which
compose the viral capsid (5% VP1; 95% VP2), are
colinear, except that VP1 contains a 227-residue amino-
terminal extension (hereafter, “unique region”), com-
pared with VP2 [5]. A transient, high viremia is ob-
served in individuals after infection with B19, followed
by the development, within a number of days, of B19-
specific IgM [6]; within a number of weeks, the pres-
ence of B19-specific IgG directed against linear and
conformational epitopes of viral capsid proteins VP1
and VP2, in addition to the presence of IgG directed
against NS1, is evident [3, 7, 8]. B19 infection leads to
an intriguing immunological phenomenon—a specific
loss of IgG, initially reactive against linear epitopes of
VP1 and VP2, occurs after infection [8, 9]. In fact,
specific IgG against linear epitopes of VP2 disappears
within 6–12 months after infection [8]. More dramat-
ically, there is a near-total diminution of NS1-specific
IgG in previously infected individuals [10]. It is, there-
fore, firmly established that detection of B19-specific
IgG against conformational epitopes is currently the
most reliable method for the detection of previous in-
fection with, and probable immunity to, B19. However,
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the reason for the postinfection loss of IgG reactivity against
linear epitopes of B19 capsid proteins has not yet been eluci-
dated, and few mechanisms that would explain this loss have
been suggested [8].
Recently, considerable effort has been directed toward the elu-
cidation of the nature of the T cell response to B19 and toward
the definition of T cell epitopes, yet the nature of B cell memory
directed against B19 remains unclear [11, 12]. Memory B cells
make a significant contribution to protective immunity and are
characterized in terms of (1) a rapid proliferative response,
accompanied by cellular differentiation after antigen reexpo-
sure, to produce affinity-matured, antibody-secreting plasma
cells; (2) a lower activation threshold, compared with that of
naive B cells, in response to cytokine and antigen; and (3) an
absence of spontaneous immunoglobulin secretion. Recently,
the identification of antigen-specific memory B cells against
vaccine antigens (diphtheria and tetanus), whereby isolated
peripheral-blood mononuclear cells (PBMCs) were nonspecif-
ically stimulated by bacterial antigens and interleukin-2 (IL-2),
followed by the specific detection of antigen-specific memory
B cells, has been described [13]. This approach may also prove
to be useful in the elucidation of virus-specific B cell–mediated
immunity.
Although B19 linear epitope–specific IgG is absent in pre-
viously infected individuals, it is currently unclear whether B
cell–memory response is ever established against linear or con-
formational epitopes of B19 proteins in infected individuals.
Furthermore, in the absence of reliable cell-culture techniques
for the detection of B19, no method is currently available for
the confirmation of either past exposure to the virus or serology
results for plasma cell–derived B19-specific IgG. Here we de-
scribe the investigation of B cell memory against B19, an in-
vestigation using a B cell enzyme-linked immunospot (ELISpot)
assay to enumerate circulating B cells that are specific to either
conformational or linearized B19 capsid proteins. This tech-
nique could also be used to define the immune status achievable
with candidate B19 vaccines and to aid in the design of im-
munization protocols that adequately induce mature immune
responses and so ensure long-lasting protection. Data are pre-
sented that further our knowledge of B cell memory directed
against specific viral antigens; the use of a B19-specific B cell
ELISpot assay offers the possibility that past exposure to, and
infection with, B19 can be confirmed.
SUBJECTS, MATERIALS, AND METHODS
Study population. Heparinized venous-blood samples (10 mL;
) were drawn from a cohort of healthy adult volunteersnp 22
(mean age, 26 years; age range, 21–41 years) and were processed
2 h after collection. Prior to the collection of samples, consent
was obtained from all volunteers, and approval was obtained
from the ethics committee of the National University of Ireland,
Maynooth. The human-experimentation guidelines of the au-
thors’ institution were followed in the conduct of this research,
as were the animal-experimentation guidelines of the government
of Ireland’s Department of Health and Children.
Antigens. B19 recombinant proteins VP1, VP2, and NS1
were produced in, and purified from, Spodoptera frugiperda (Sf9)
insect cells infected with recombinant baculovirus encoding ei-
ther VP1, VP2, or NS1 open-reading frames, as described else-
where [10, 14–16].
Antibody assays. Plasma obtained from blood samples was
used to evaluate B19-specific IgG reactivity to the viral capsid
proteins. B19-specific IgG against native VP2 (VP2-N) was de-
termined by a commercial EIA (Biotrin International) and was
quantified using the World Health Organization B19-specific
IgG international-standard preparation (code 93/724; National
Institute for Biological Standards and Control). IgG reactivity
against denatured VP1 (VP1-D) and denatured VP2 (VP2-D)
was determined by EIA formats developed in-house, as de-
scribed elsewhere [16]. In brief, microtiter plates (Nalge Nunc)
were coated overnight at 4C with either VP1-D or VP2-D.
The microtiter plates were then washed and blocked before
being incubated with plasma samples that had been diluted
1:100 in PBS containing 0.05% (v/v) Tween-20 (PBST); the
plates were then incubated with horseradish peroxidase (HRP)–
conjugated anti–human IgG (Dako) for 30 min. After a wash
step (4 washes with PBST), tetramethylbenzidine substrate was
added to the wells, which were then incubated for 10 min. The
enzymatic color reaction was terminated by adding 1 N H2SO4.
The absorbance was read at 450 nm and at 630 nm. Immu-
noassay cutoffs were defined as the absorbance plus 2 SDs
greater than the mean absorbance, as determined from a panel
of B19-specific IgG–negative specimens. Results are expressed
as index values (IV), calculated as specimen absorbance divided
by cutoff absorbance (IV !1, B19-specific IgG negative; IV 11.0,
B19-specific IgG positive).
Avidity assays. The avidity of B19-specific IgG antibody
against VP1 and VP2 was determined in the same manner as
was used in the antibody assays described above, but with a
modification of the wash step. Microtiter plates were coated as
described above and were then incubated with plasma samples
in duplicate on 2 separate plates. After being incubated, the
plates were washed differently to determine avidity; one plate
was washed with 4 M of urea and PBST for 5 min, whereas
the other plate was washed with only PBST for 5 min. Both
plates were then washed twice with only PBST for 5 min. Anti-
gen-bound IgG was detected as described above, by use of HRP
conjugate. The avidity index (AI) was calculated as the ratio
of the absorbance obtained for the plate washed with urea and
PBST and that obtained for the plate washed with only PBST;
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AI is expressed as a percentage. High and low AIs are indicative
of past and recent infection, respectively.
Isolation of PBMCs and stimulation of cells. PBMCs were
isolated by density-gradient centrifugation, as described else-
where [17]. PBMCs ( cells/mL) were cultured for 5 days65 10
in complete RPMI 1640, in the presence of heat-killed Staph-
ylococcus aureus Cowan strain I cells (SACs) (Calbiochem) di-
luted 1:5000 and of 10 ng of IL-2/mL (Serotec). SACs and IL-
2 jointly function to induce generalized antibody production
in resting memory B cells [13].
B cell–memory ELISpot assay. After culture, cells were
washed and quantified by ELISpot assay using a modification
of a protocol described elsewhere [13]. Nitrocellulose-lined 96-
well plates (Millipore) were coated with either VP2-N (10 mg/
mL), VP2-D (10 mg/mL), VP1-D (10 mg/mL), or rabbit anti–
human IgG (10 mg/mL; Dako) in 50 mmol of sodium carbonate
buffer/L (pH 9.6) overnight at 4C. Rabbit anti–human IgG
facilitated detection of the total number of IgG-secreting B cells
for each donor, to ensure that memory B cell activation had
occurred. Plates were washed with PBS and then were blocked
with 20% (v/v) fetal calf serum in RPMI 1640. After stimu-
lation, cells (at concentrations of , , and 11046 51 10 1 10
cells/well) were added to the plates, incubated in complete
RPMI 1640 for 18 h at 37C, and then removed by washing
with PBS. Secreted IgG was detected using biotinylated rabbit
anti–human IgG (1 mg/mL) and subsequent use of streptavidin-
conjugated alkaline phosphatase (Sigma-Aldrich) at a dilution
of 1:1000 (1% [w/v] bovine serum albumin in PBS). Spots
were developed by the addition of 5-bromo-4-chloro-3-indolyl
phosphate/p-nitroblue tetrazolium chloride substrate (Sigma-
Aldrich) to the wells and were counted after 15 min by light
microscopy. The numbers of spots in triplicate wells were av-
eraged, and resultant data were reported as the mean number
of spot-forming cells (SFCs) per 1 million starting cells (SCs).
Murine serology and B cell–memory response. BALB/c
mice were immunized intraperitoneally with either 50 mg of
VP1-D ( ) or 50 mg of VP2-N ( ) in Freund’s com-np 3 np 3
plete adjuvant (Sigma-Aldrich). The murine IgG response was
analyzed at weeks 6 and 32 after immunization, by the antibody
assays described above for the human antibody response, except
that an anti–mouse IgG–HRP conjugate (Bio-Rad Laborato-
ries) was used. Murine B cell ELISpot assays were also per-
formed on isolated spleen cells taken from individual mice,
according to the protocol described above, except that (1) goat
anti–mouse IgG (Sigma-Aldrich) was used to capture total B
cell–derived IgG and (2) biotinylated rabbit anti-mouse IgG (1
mg/mL) was used to detect secreted IgG.
Statistical analysis. Frequencies of the level of SFCs ob-
tained from the ELISpot assays were subjected to comparative
analysis by Student’s t test; comparison of antibody data with
ELISpot results was assessed by Pearson’s correlation; titers of
mouse antibody were compared by a repeated-measure analysis
of variance. The statistical-software package GraphPad InStat
was used for all analyses.
RESULTS
The present study was designed to investigate whether B cell
memory is established against B19. It can be seen from figure
1 that all individuals who were seropositive for B19-specific
IgG ( ; table 1) exhibit strong evidence of B cell memory,np 17
whereas individuals who were seronegative for B19-specific IgG
( ; table 1) do not appear to harbor any significant levelnp 5
of B19-specific memory B cells. In fact, the difference between
the level of SFCs in seropositive individuals and that in sero-
negative individuals was statistically significant for both VP2-N
and VP1-D ( and , respectively); a total of 15Pp .003 Pp .009
seropositive individuals exhibited B19-specific memory (mean
 SD, 87154 SFCs/1 million SCs; range, 7.8–606 SFCs/1
million SCs) against VP2-N, and 12 seropositive individuals
exhibited B19-specific memory against VP1-D (mean  SD,
69110 SFCs/1 million SCs; range, 4.4–406 SFCs/1 million
SCs) (figure 1). There was no statistically significant difference
between the number of memory B cells directed against VP1-
D and that directed against VP2-N ( ); however, thePp .2
greatest number of SFCs were specific to VP2-N and were
evident in 2 individuals (S008, mean  SD, SFCs/222 16.4
1 million SCs; S014, mean  SD, SFCs/1 million606 69
SCs). B cell memory could not be detected in the absence of
IL-2 and SAC stimulation prior to ELISpot analysis (data not
shown); neither was there evidence of memory directed against
NS1 in 5 individuals (S008, S009, S010, S011, and S012) se-
ropositive for B19-specific VP2 IgG, all of whom exhibited B
cell memory against either VP1-D or VP2-N.
When the IgG avidity of the 5 specimens (S003, S008, S010,
S013, and S014) positive, by EIA, for B19-specific IgG against
VP1-D were analyzed, a statistically significant positive corre-
lation ( ) was found between the level of SFCs andrp 0.96
avidity. Such a correlation was not observed for VP2-N–specific
avidity ( ); neither was there a correlation between therp 0.27
level of SFCs and the endpoint titer of B19-specific IgG (data
not shown).
Although 3 individuals (S003, S008, and S012) had circu-
lating VP2-D IgG (detectable by EIA in all 3 [table 1] and by
Western blot in S003 only), there was no evidence of any sig-
nificant B cell memory against linear epitopes of VP2 (fig-
ure 1). Furthermore, the level of memory B cells observed in
this cohort was not significantly different from that observed
in seronegative individuals ( ). Induction of memoryP 1 .999
against epitopes of the B19 capsid proteins is, therefore, con-
fined to 2 regions—linear epitopes in the unique region of VP1
and conformational epitopes present on VP2-N. VP1 cannot
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Figure 1. Human parvovirus B19 (B19)–specific B cell memory in blood samples obtained from seropositive (SP) and seronegative (SN) volunteer
donors. Results of B cell memory are expressed as B19-specific spot-forming cells (SFCs)/1 million starting cells (SCs) and are the mean  SD of
triplicate wells. ELISpot microplates were coated with either native VP2 (black bars), denatured VP1 (diagonally shaded bars), or denatured VP2
(horizontally shaded bars).
be purified in a conformationally intact form, and so no in-
formation with respect to the conformational B cell epitopes
of this protein is available at present.
To test the hypothesis that there is a species-specific differ-
ence between the antigenicity of linear and conformational epi-
topes of the B19 capsid proteins and to explore the appropriate-
ness of animal-model systems in B19 immunogenicity studies,
a murine model was employed. The murine B19-specific IgG
response against either VP1 ( ) or VP2 ( ) was an-np 3 np 3
alyzed at weeks 6 and 32 after immunization. Equally strong
responses were observed against both linear (endpoint titer,
log10 4.0) and conformational (endpoint titer, log10 4.6) epitopes
of VP2 at week 6 (figure 2A); the antibody response against
linear epitopes showed no evidence of waning, because analysis
of VP2-specific IgG reactivity at week 32 revealed no statistically
significant difference ( ) between conformational epi-Pp .1
topes and linear epitopes (VP2-N endpoint titer, log10 4.9; VP2-
D endpoint titer, log10 4.2). In addition, there was equally strong
immunoreactivity against VP1-D at week 6 (endpoint titer, log10
3.9) and at week 32 (endpoint titer, log10 4.1) (figure 2A).
Similar results were obtained in murine B cell ELISpot analysis.
However, unlike the human response to B19 infection, where
there was no evidence of memory against linear epitopes of VP2,
in the murine response there was strong B cell memory against
both the conformational and linear epitopes of VP2 (mean 
SD, and SFCs/1 million SCs, respectively) at103 55 129 11
week 32 after immunization (figure 2B). B cell memory against
VP1-D was also strongly induced (mean  SD, SFCs/104 6
1 million SCs) and was not significantly different ( ) fromPp .8
the response induced against VP2-N. These data indicate a strong,
long-lasting, intrinsic antigenicity of the B19 capsid proteins that
is directed against both the conformational and linear epitopes.
DISCUSSION
The present study is the first to demonstrate B cell mem-
ory against B19 VP2 and against the unique region of VP1.
We have shown that B cell memory is maintained against the
unique region of VP1, even in the absence of any detectable
antibody against the unique region. In addition, we have shown
a statistically significant positive correlation ( ) betweenrp 0.96
the level of antibody directed against the unique region of VP1
and the level of SFCs. Finally, whereas B cell memory is not
maintained against linear epitopes of VP2, we have shown that,
in immunized mice, B cell memory does persist against linear
epitopes of VP2. This result suggests that interaction between
VP2 itself and the human immune system (or, conceivably, be-
tween other B19 proteins [e.g., NS1] and the human immune
system) during infection may be responsible for the absence of
B cell memory against linear epitopes of VP2.
IgG reactivity against conformational epitopes of VP2 is now
accepted as the most reliable indicator of past infection with
B19 [9, 18, 19]. In the present study, 88% (15/17) of individuals
demonstrating IgG reactivity against VP2-N exhibited B cell
memory against VP2-N, whereas only 71% (12/17) showed
evidence of B cell memory against the unique region of VP1.
The absence of detectable B cell memory against linear epitopes
of VP2 was quite marked, especially since 18% (3/17) of se-
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Table 1. Summary of donor serology: IgG response, in plasma
obtained from adult volunteers, against the parvovirus B19 (B19)
capsid proteins VP1 and VP2, in native and denatured forms.
Donor ( )np 22
Titer of
B19-specific
IgG against
VP2-N, IU/mL
Index valuea
VP2-D VP1-D
B19-specific IgG seropositive
S001 90 0.5 0.5
S002 49 0.5 0.6
S003 122 2.3 1.2
S004 120 0.5 0.6
S005 118 0.5 0.3
S006 21 0.6 0.5
S007 18 0.4 0.4
S008 147 1.8 2.0
S009 27 0.4 0.4
S010 105 1.0 1.2
S011 43 0.6 0.6
S012 53 1.2 0.5
S013 68 0.6 0.8
S014 140 0.6 1.2
S015 160 0.2 0.8
S016 152 0.5 0.7
S017 38 0.2 0.3
B19-specific IgG seronegative
S018 1 0.4 0.4
S019 1 0.5 0.7
S020 3 0.4 0.3
S021 2 0.4 0.3
S022 1 0.1 0.4
NOTE. VP1-D, denatured VP1; VP2-D, denatured VP-2; VP2-N, native
VP-2.
a Index values are calculated as specimen absorbance divided by cutoff
absorbance.
Figure 2. A, Murine IgG response to parvovirus B19 after a single
intraperitoneal immunization with B19 VP1 and VP2 antigens. At weeks
6 and 32 after immunization, thoracic-blood samples were taken from
mice and levels of IgG specific for native VP2 (VP2-N), denatured VP2
(VP2-D), and denatured (VP1-D) in serum were determined by ELISA.
Results are expressed as the mean log10 endpoint titers of antibody,
calculated by regression of the straight part of the curve of OD450/630 nm
versus serum dilution, to a cutoff of 2 SDs above background control
values obtained from serum in naive mice. B, B19–specific B cell memory
in immunized mice at week 32 after immunization. Results of B cell
memory are expressed as B19-specific spot-forming cells (SFCs)/1 million
starting cells (SCs) and are the mean  SD of triplicate wells.
ropositive individuals exhibited IgG reactivity against linear epi-
topes of VP2. To our knowledge, the present study provides
the first confirmation that B cell memory is never established
against linear epitopes of VP2 and adds further credence to the
concept that long-lived plasma cells and memory B cells are
2 separate forms of independently controlled immunological
memory [20, 21]. A recent report of the enumeration, in the
adenoids of children, of IgG memory B cells against 4 pneu-
mococcal antigens has also shown a broad antigen-specific re-
sponse, which suggests that certain antigens are more likely
than others to elicit the establishment of B cell memory [22].
It is also likely that the B19-specific B cell ELISpot assay could
find application in the confirmation of past infection with B19.
It is well established that the humoral immune response to
B19 evolves gradually, from a population of antibodies with
reactivity against both linear and conformational epitopes to
one with predominantly conformational-epitope specificity
[8, 9, 23, 24]. In the present study, although only 5 individuals
exhibited, by either microplate immunoassay or Western blot,
IgG reactivity against VP1-D, 12 individuals displayed a positive
B cell–memory response against the unique region of VP1. It
has been well documented that the unique region of VP1 ex-
hibits characteristics associated with immunodominance, in-
cluding the stimulation of ex vivo T cell proliferation and of
cytokine secretion [16]. In addition, this region appears to elicit
neutralizing-antibody responses more effectively than do other
linear epitopes of B19 [3]—specifically, more effectively than
the VP1 region corresponding to aa 60–100 [25]. Our analysis
further reveals a statistically significant correlation between an-
tibody avidity against the unique region of VP1 and the level of
SFCs specific for VP1-D, indicating that the strength of the an-
tibody response against the unique region of VP1 may be related
to the induction of B cell memory. Conceivably, the level of
reexposure to B19—or, perhaps, B19 persistence—could account
for the different B cell responses to B19 infection in previously
infected individuals.
Even though 3 of the individuals tested (S003, S008, and
S012) displayed IgG reactivity against linear epitopes of VP2
and had high avidity (AIs, 80.7, 93.2, and 40.2, respectively),
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there was no evidence, by ELISpot assay, of memory against
these VP2-specific epitopes. This phenomenon suggests that
the observed IgG reactivity is a product of long-lived plasma
cells that are established early in the response and is not a
product of memory B cells, which are mostly established after
undergoing selection in the germinal center [26]. The induction
of memory after infection may favor conformational epitopes
over linear epitopes because of simple stoichiometry [27]. Lin-
ear epitopes are less likely to be multivalent, thereby reducing
B cell receptor cross-linking; this reduction, in turn, would lead
to the imposition of a selective disadvantage in the competitive
environment of the germinal center [28]. This phenomenon is
exemplified in equine infectious anemia virus infection—al-
though the initial antibody response is predominantly directed
against linear determinants of the envelope protein, within 1–
2 months after infection the IgG reactivity gradually progresses
to a more conformationally dependent antibody population
[29]. In addition, conformational epitopes are likely to exist
on intact capsids, which, when internalized, are processed by
specific B cells, resulting in the presentation of a broader range
of peptides to specific T cells [16]. Therefore, even though the
T cells recognize only linear peptides, assistance would be pref-
erentially directed toward B cells that are specific for confor-
mational or discontinuous epitopes. This situation is thought
to occur in immunity against polioviruses, where B cell memory
against conformational epitopes is central to protection but
requires support by T cells that recognize peptides from either
internal or external capsid proteins [30, 31]. On the other hand,
there may be other explanations for this phenomenon; for ex-
ample, it is known that strong immune-activation signals can
induce lymphocyte apoptosis [32]. Linear epitopes of VP2 can
elicit a strong initial IgG response, and it is conceivable that such
stimulation could induce B cell apoptosis; however, this scenario
seems unlikely, given that no loss of memory is observed in
immunized mice. Alternatively, the lack of establishment of B
cell memory against linear epitopes of VP2 could be due to the
absence of a “maintenance” signal, essential to the maintenance
of mature B cells, from a functional B cell receptor [33], although
it is difficult to construct a scenario, beyond those described
above, in which this would occur selectively.
Despite the absence of memory against linear epitopes of
VP2 in any of the human specimens tested, in the murine model
there was a strong B cell–memory response induced against
VP2-D and VP1-D. The maintenance of high titers of antibody
at week 32 after immunization (VP2-D endpoint titer, log10 4.2;
VP1-D endpoint titer, log10 4.1) (figure 2A), in parallel with a
high level of SFCs at week 32 for VP2-D (mean  SD, 129
11 SFCs/1 million SCs) (figure 2B), demonstrates that both
VP1 and VP2 possess linear epitopes that are intrinsically im-
munogenic and that facilitate the establishment of B cell mem-
ory. It is interesting to note that the level of SFCs observed in
the present study after mice were immunized with B19 antigens
is comparable to that observed (50–100 SFCs/1 million SCs)
when mice were naturally infected with lymphocyte choriomen-
ingitis virus [34]. Although this analogous B cell–memory re-
sponse in infection and in immunization is significant, it does
not help explain why specific epitope reactivity is lost after
natural infection in humans. Furthermore, these results illus-
trate the difference between the immunity generated by infec-
tion in the natural host, and the difficulty of using a murine
model to assess immunogenicity. The different responses ob-
served in the human and murine models may be partly ex-
plained by the fact that Freund’s adjuvant is powerful and,
therefore, may have induced stronger immunoreactivity to both
linear and conformational epitopes than would be seen in nat-
ural infection. In addition, the route of delivery was different
in each model: in the murine model, delivery was intraperi-
toneal (and, therefore, systemic), whereas the delivery was most
likely mucosal in natural infection. Replicating virus may be
responsible for inducing in humans host-specific cellular factors
that cause specific B cell deletion and, therefore, antibody loss
against linear regions of VP2. Because NS1 is a cytotoxic protein
[35] that is capable of inducing apoptotic effects in the host
[36], the possibility that NS1 might play a role in the loss of
epitope specificity cannot be ruled out.
Initial B19-vaccine studies that have been performed in mice,
guinea pigs, and rabbits [37] have focused on the level of cir-
culating B19 antibody and its associated ability to neutralize
the virus. Although a correlation has been observed between
the development of antibody against the unique region of VP1
and neutralization of the virus [38], the differing natures of
the human and murine immune responses to B19 antigens
would suggest that caution be taken in the extrapolation and
application of the results of nonprimate vaccine studies to hu-
mans. More recently, the in vitro efficacy of a candidate vaccine
for B19 (MEDI-491; Medimmune) has been demonstrated; in
a double-blind, phase 1 trial, 24 volunteers all produced neu-
tralizing antibody after 3 immunizations [39]. Despite the de-
velopment of a candidate B19 vaccine [37, 39], there has been
no analysis of the potential role that memory B cells may play
in either the efficacy of B19-subunit vaccines against infection
or in the persistence of immunological protection. The B19-
specific B cell ELISpot assay presented here would be an ideal
ex vivo diagnostic tool for the evaluation of whether candidate
B19-subunit vaccines have the capacity to establish B cell mem-
ory. Such an approach would be particularly important for
understanding the interplay between individual titers of B19-
specific IgG and B19-specific memory B cells, both to establish
the relative importance of each parameter in combating B19
infection in immunized individuals and to define correlates of
protection. It would also have important implications in the
design of booster strategies, as has been the case in vaccine
Parvovirus B19 B Cell Memory • JID 2004:189 (15 May) • 1879
evaluation for tetanus toxoid and diphtheria, where it has been
concluded that the level of antigen-specific SFCs is an indirect
measure of immunological memory [13].
To summarize, analysis of the induction of B cell memory
after B19 infection shows that, although B cell memory is
strongly maintained against conformational epitopes of the ma-
jor capsid protein VP2, it is not maintained against its linear
epitopes. Furthermore, although previously infected individuals
may no longer have circulating IgG against the unique region
of VP1, memory B cells persist and have the potential to mount
a humoral response on reexposure to B19. Additional studies
of selected patient cohorts (e.g., persistently infected individuals
or individuals with a B19 infection of defined duration) should
further elucidate the mechanism and extent of the absence of
B cell memory against linear epitopes of B19 capsid proteins.
The findings of the present study have implications for both
the confirmation of B19 infection and the development of a
vaccine to protect against B19 infection.
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